Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800589 | 0.95 | NAMPT (0.42) | ALDH1A1TSHRNAMPTSMN1; SMN2HTR1A | |
| SCHEMBL6795268 | 0.94 | NPC1 (0.38) | TSHRNAMPTSMN1; SMN2KMT2ADRD3 | |
| SCHEMBL6793648 | 0.88 | CDK2 (0.33) | RAB9AHTR2ACYP1A2CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL6791633 | 0.88 | ALDH1A1 (0.44) | ALDH1A1TSHRNAMPTSMN1; SMN2RAB9A | |
| SCHEMBL6800306 | 0.88 | NAMPT (0.38) | ALDH1A1NAMPTSMN1; SMN2KMT2AHTR1A | |
| SCHEMBL6791548 | 0.87 | CYP1A2 (0.33) | ALDH1A1TSHRNAMPTCYP1A2CYP3A4 | |
| SCHEMBL1655698 | 0.87 | CYP1A2 (0.30) | CYP1A2CYP3A4 | |
| SCHEMBL6791910 | 0.87 | ROCK2 (0.38) | ALDH1A1TSHRNAMPTRAB9AKMT2A | |
| SCHEMBL6794266 | 0.87 | KMT2A (0.41) | ALDH1A1TSHRSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6794582 | 0.86 | ROCK2 (0.43) | ALDH1A1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | ALDH1A1 4449/4885TSHR 3404/4885NAMPT 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.